Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N3VR
|
|||
| Former ID |
DAP001271
|
|||
| Drug Name |
Voriconazole
|
|||
| Synonyms |
VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Invasive aspergillosis [ICD-11: 1F20.0; ICD-10: B44.0, B44.8; ICD-9: 117.3] | Approved | [1] | |
| Therapeutic Class |
Antifungal Agents
|
|||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H14F3N5O
|
|||
| Canonical SMILES |
CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
|
|||
| InChI |
1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
|
|||
| InChIKey |
BCEHBSKCWLPMDN-MGPLVRAMSA-N
|
|||
| CAS Number |
CAS 188416-29-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9824, 618929, 7847644, 8194731, 12014673, 14754154, 14900759, 26719857, 43127923, 46386721, 46506421, 49681678, 49830865, 50065685, 53790739, 57318277, 58107314, 79258320, 92308499, 92712543, 93165418, 99437153, 103042056, 103188976, 104350892, 109692905, 117510444, 118048601, 121361066, 124658937, 124757251, 124766492, 125083219, 125164055, 126592905, 126625471, 126656629, 126670609, 127494461, 134338507, 135029377, 136340251, 136367733, 137006421, 140298163, 144076218, 144205794, 152164501, 160870955, 160963927
|
|||
| ChEBI ID |
CHEBI:10023
|
|||
| ADReCS Drug ID | BADD_D02369 | |||
| SuperDrug ATC ID |
J02AC03
|
|||
| SuperDrug CAS ID |
cas=137234629
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.552; p = 0.025). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.727; p = 0.032). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.635; p = 0.02). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.605; p = 0.045). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.523; p = 0.038). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.526; p = 0.048). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.588; p = 0.03). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.505; p = 0.047). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.618; p = 0.016). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.451; p = 0.022). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.477; p = 0.008). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Odoribacter splanchnicus (log2FC = -0.396; p = 0.044). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Voriconazole can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.373; p = 0.042). | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Candida Cytochrome P450 51 (Candi ERG11) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53. | |||
| REF 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.